Following DTx West 2023 in San Mateo, California, back in February, Woebot Health’s chief clinical officer Athena Robinson spoke with pharmaphorum about the conversations had at the event,
Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeu
As the Frontiers Health 2022 conference in Milan on 20th to 21st October approaches this week, pharmaphorum has been catching up with members of the event’s Steering Committee to find out m
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut